1
|
Chen YQ, Xu XF, Xu JW, Di TY, Wang XL, Huo LQ, Wang L, Gu J, Zhou GH. A high-quality model for predicting the prognosis of breast neuroendocrine carcinoma to help clinicians decide on appropriate treatment methods: A population-based analysis. Transl Oncol 2022; 22:101467. [PMID: 35700595 PMCID: PMC9198476 DOI: 10.1016/j.tranon.2022.101467] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2022] [Revised: 05/30/2022] [Accepted: 06/05/2022] [Indexed: 12/01/2022] Open
Abstract
The incidence of breast neuroendocrine carcinoma (NEC) was approximately 1.96–2.37%. Breast NEC had poor prognosis than breast invasive ductal carcinoma (IDC). Patients with breast NEC may benefit from surgery plus chemotherapy. Efficient models were constructed to guide the treatment of breast NEC.
Background Breast neuroendocrine carcinoma (NEC) is a rare malignancy with unclear treatment options and prognoses. This study aimed to construct a high-quality model to predict overall survival (OS) and breast cancer-specific survival (BCSS) and help clinicians choose appropriate breast NEC treatments. Patients and methods A total of 378 patients with breast NEC and 349,736 patients with breast invasive ductal carcinoma (IDC) were enrolled in the Surveillance, Epidemiology, and End Results (SEER) database between 2010 and 2018. Propensity score matching (PSM) was performed to balance the clinical baseline. Prognostic factors determined by multivariate Cox analysis were included in the nomogram. C-index and calibration curves were used to verify the performance of the nomogram. Results Nomograms were constructed for the breast NEC and breast IDC groups after PSM. The C–index of the nomograms ranged from 0.834 to 0.880 in the internal validation and 0.818–0.876 in the external validation, indicating that the nomogram had good discrimination. The risk stratification system showed that patients with breast NEC had worse prognoses than those with breast IDC in the low-risk and intermediate-risk groups but had a similar prognosis that those in the high-risk group. Moreover, patients with breast NEC may have a better prognosis when undergoing surgery plus chemotherapy than when undergoing surgery alone or chemotherapy alone. Conclusions We established nomograms with a risk stratification system to predict OS and BCSS in patients with breast NEC. This model could help clinicians evaluate prognosis and provide individualized treatment recommendations for patients with breast NEC.
Collapse
Affiliation(s)
- Yu-Qiu Chen
- Department of Clinical Pharmacy, Affiliated Jinling Hospital, State Key Laboratory of Analytical Chemistry for Life Science and Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing 210002, China; Research Institute of General Surgery, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu 210002, China
| | - Xiao-Fan Xu
- Research Institute of General Surgery, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu 210002, China
| | - Jia-Wei Xu
- Research Institute of General Surgery, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu 210002, China
| | - Tian-Yu Di
- Research Institute of General Surgery, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu 210002, China
| | - Xu-Lin Wang
- Research Institute of General Surgery, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu 210002, China
| | - Li-Qun Huo
- Research Institute of General Surgery, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu 210002, China
| | - Lu Wang
- Research Institute of General Surgery, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu 210002, China
| | - Jun Gu
- Research Institute of General Surgery, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu 210002, China.
| | - Guo-Hua Zhou
- Department of Clinical Pharmacy, Affiliated Jinling Hospital, State Key Laboratory of Analytical Chemistry for Life Science and Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing 210002, China; Department of Clinical Pharmacy, Affiliated Jinling Hospital, School of Pharmacy, Southern Medical University, Guangzhou 510515, China.
| |
Collapse
|
2
|
Safini F, Bouchbika Z, Bennani Z, Belkheiri S, Attar HE, Benchakroun N, Jouhadi H, Tawfiq N, Sahraoui S, Benider A. [Primary large cell neuroendocrine carcinoma of the breast: a rare tumor in humans]. Pan Afr Med J 2017; 25:205. [PMID: 28292162 PMCID: PMC5326194 DOI: 10.11604/pamj.2016.25.205.10366] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2016] [Accepted: 08/04/2016] [Indexed: 01/31/2023] Open
Abstract
Le carcinome neuroendocrine à grandes cellules primitif du sein est une entité extrêmement rare. Moins de dix cas ont été rapportés dans la littérature. Nous présentons un nouveau cas survenu chez un homme de 61 ans qui s’est présenté pour une tumeur localement avancée du sein droit d’emblée métastatique aux poumons et à la plèvre, classée cT4bN1M1. Le patient avait reçu huit cycles de chimiothérapie à base de Docetaxel tous les 21 jours, avec une bonne réponse clinique et radiologique (>50%), puis mis sous hormonothérapie à base de tamoxifène avec une stabilisation pendant 18 mois. L’étude immuni-histochimique reste indispensable pour déterminer la nature neuroendocrine de cette tumeur. Le traitement n’est pas bien codifié vu la rareté de ce type de cancer.
Collapse
Affiliation(s)
- Fatima Safini
- Service d'Oncologie et de Radiothérapie, CHU Ibn Rochd, Casablanca, Maroc
| | - Zineb Bouchbika
- Service d'Oncologie et de Radiothérapie, CHU Ibn Rochd, Casablanca, Maroc
| | - Zineb Bennani
- Service d'Oncologie et de Radiothérapie, CHU Ibn Rochd, Casablanca, Maroc
| | - Sara Belkheiri
- Service d'Oncologie et de Radiothérapie, CHU Ibn Rochd, Casablanca, Maroc
| | - Hicham El Attar
- Laboratoire d'Etude Anatomopathologique Moulay Driss Premier, Casablanca, Maroc
| | - Nadia Benchakroun
- Service d'Oncologie et de Radiothérapie, CHU Ibn Rochd, Casablanca, Maroc
| | - Hassan Jouhadi
- Service d'Oncologie et de Radiothérapie, CHU Ibn Rochd, Casablanca, Maroc
| | - Nezha Tawfiq
- Service d'Oncologie et de Radiothérapie, CHU Ibn Rochd, Casablanca, Maroc
| | - Souha Sahraoui
- Service d'Oncologie et de Radiothérapie, CHU Ibn Rochd, Casablanca, Maroc
| | - Abdellatif Benider
- Service d'Oncologie et de Radiothérapie, CHU Ibn Rochd, Casablanca, Maroc
| |
Collapse
|
3
|
Primary neuroendocrine carcinoma of the breast: report of 2 cases and literature review. Radiol Case Rep 2017; 12:1-12. [PMID: 28228868 PMCID: PMC5310536 DOI: 10.1016/j.radcr.2016.12.001] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2016] [Accepted: 12/01/2016] [Indexed: 11/20/2022] Open
Abstract
Neuroendocrine tumors of the breast are very rare accounting for less than 0.1% of all breast cancers and less than 1% of all neuroendocrine tumors. Focal neuroendocrine differentiation can be found in different histologic types of breast carcinoma including in situ and invasive ductal or invasive lobular. However, primary neuroendocrine carcinoma of the breast requires the expression of neuroendocrine markers in more than 50% of the cell population, the presence of ductal carcinoma in situ, and the absence of clinical evidence of concurrent primary neuroendocrine carcinoma of any other organ. Reports discussing the imaging characteristics of this rare carcinoma in different breast imaging modalities are scarce. We present 2 cases of primary neuroendocrine carcinoma of the breast for which mammography, ultrasound, and magnetic resonance imaging findings and pathology findings are described. A review of the medical literature on this particular topic was performed, and the results are presented.
Collapse
|
4
|
Affane M, Elmorjani L, El Omrani A, Abbadi F, Rais H, Khouchani M. [Neuroendocrine carcinoma of the breast: about a case and review of the literature]. Pan Afr Med J 2016; 24:78. [PMID: 27642417 PMCID: PMC5012787 DOI: 10.11604/pamj.2016.24.78.8546] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2015] [Accepted: 04/03/2016] [Indexed: 11/11/2022] Open
Abstract
Primitive neuroendocrine carcinomas of the breast are rare tumors. They are now included in the latest WHO classification of tumors of the breast. We report the case of a 39-year old patient with tumor located in the breast. It was a locally advanced tumor that required mastectomy and ipsilateral axillary node dissection. Adjuvant chemotherapy was indicated. The evolution was marked by local progression. The patient died in a state of febrile pancytopenia after a one-year survival.
Collapse
Affiliation(s)
- Mariam Affane
- Service d'Oncologie-Radiothérapie, CHU Mohammed VI de Marrakech, Maroc
| | - Leila Elmorjani
- Service d'Oncologie-Radiothérapie, CHU Mohammed VI de Marrakech, Maroc
| | | | - Fayçal Abbadi
- Service d'Anatomo-Pathologie, CHU Mohammed VI de Marrakech, Maroc
| | - Hanane Rais
- Service d'Anatomo-Pathologie, CHU Mohammed VI de Marrakech, Maroc
| | - Mouna Khouchani
- Service d'Oncologie-Radiothérapie, CHU Mohammed VI de Marrakech, Maroc
| |
Collapse
|
5
|
Lee DH, Park AY, Seo BK, Kim YS, Lee KY, Cha SH. Primary Neuroendocrine Carcinoma of the Breast with Clinical Features of Inflammatory Breast Carcinoma: A Case Report and Literature Review. J Breast Cancer 2015; 18:404-8. [PMID: 26770249 PMCID: PMC4705094 DOI: 10.4048/jbc.2015.18.4.404] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2015] [Accepted: 10/26/2015] [Indexed: 11/30/2022] Open
Abstract
Primary neuroendocrine carcinoma of the breast (NECB) is a very rare type of invasive breast carcinoma. Most NECBs appear on breast imaging as solid masses of varied shapes and margins, and have worse clinical outcomes than does invasive ductal carcinoma, not otherwise specified. However, there have been no reports to date regarding NECB with features of inflammatory breast carcinoma. Here, we describe the clinical, radiol-ogic, and pathologic findings of the first reported case of primary NECB presenting as inflammatory breast carcinoma. The patient complained of diffuse right breast enlargement and erythema. Mammography identified severe breast edema and axillary lymphadenopathy. Ultrasound detected an irregular, angular, hypoechoic mass with dermal lymphatic dilatation. On magnetic resonance imaging, the mass had rim enhancement and the entire right breast showed heterogeneous enhancement with malignant kinetic features. Pathology identified the mass as a primary NECB with positive for synaptophysin, CD56, estrogen and progesterone receptors.
Collapse
Affiliation(s)
- Do Hyung Lee
- Department of Radiology, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea
| | - Ah Young Park
- Department of Radiology, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea.; Kangwon National University Graduate School, Chuncheon, Korea
| | - Bo Kyoung Seo
- Department of Radiology, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea
| | - Young Sik Kim
- Department of Pathology, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea
| | - Ki Yeol Lee
- Department of Radiology, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea
| | - Sang Hoon Cha
- Department of Radiology, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea
| |
Collapse
|
6
|
Yoshimura N, Sasada T, Yonehara S. Primary Large-Cell Neuroendocrine Carcinoma of the Breast Occurring in a Pre-Menopausal Woman. Breast Care (Basel) 2015; 10:281-3. [PMID: 26600766 DOI: 10.1159/000431070] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023] Open
Abstract
BACKGROUND Primary large-cell neuroendocrine carcinoma of the breast (LCNEC-breast) in pre-menopausal women is extremely rare. CASE REPORT A 34-year-old woman presented with a mass in the left breast that was diagnosed as neuroendocrine carcinoma by needle biopsy. Computed tomography revealed no lymph node swelling or distant organ metastasis. Left mastectomy and sentinel lymph node biopsy were performed and metastasis to the axial lymph node was detected. Left axillary lymph node dissection was performed and histopathological and immunohistochemical examination revealed that the tumor was an LCNEC-breast, which was 6.0 cm in size and positive for the neuroendocrine markers (neuron-specific enolase, chromogranin A, and synaptophysin). The tumor cells were hormone-receptor positive and HER2 negative. The patient refused any adjuvant hormonal therapy, chemotherapy or radiotherapy. She has been followed up for 4 years without medication, and no recurrence has been noted. CONCLUSION We present a case of LCNEC-breast in a 34-year-old woman. Our case represents the youngest woman with LCNEC-breast reported in the English literature.
Collapse
Affiliation(s)
- Noriko Yoshimura
- Department of Surgery, Onomichi General Hospital, Hiroshima, Japan
| | - Tatsunari Sasada
- Department of Surgery, Onomichi General Hospital, Hiroshima, Japan
| | - Shuji Yonehara
- Department of Pathology, Onomichi General Hospital, Hiroshima, Japan
| |
Collapse
|
7
|
Janosky M, Bian J, Dhage S, Levine J, Silverman J, Jors K, Moy L, Cangiarella J, Muggia F, Adams S. Primary large cell neuroendocrine carcinoma of the breast, a case report with an unusual clinical course. Breast J 2015; 21:303-7. [PMID: 25823996 DOI: 10.1111/tbj.12403] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Large cell neuroendocrine carcinoma of the breast (NECB) is an extremely rare type of breast cancer; little is known about effective chemotherapies, and data on pathologic response to treatment are unavailable. We report the case of a 34-years-old woman with large cell NECB with initial clinical and pathologic evidence of treatment response to anthracycline-containing neo-adjuvant therapy. Histologic reassessment early during anthracycline chemotherapy revealed cell death with necrosis of 50% of the tumor cells seen in the biopsy specimen. After completing neo-adjuvant chemotherapy, the patient underwent breast-conserving surgery. Pathologic evaluation of the surgical specimen showed a partial response but margins were positive for residual carcinoma. Despite repeated neo-adjuvant chemotherapy, radiotherapy, and surgical resection, the tumor grew rapidly between surgeries and recurred systemically. Therefore, we review the literature on large cell NECB and its treatment options.
Collapse
Affiliation(s)
- Maxwell Janosky
- New York University Cancer Institute, NYU School of Medicine, New York, New York
| | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Primary neuroendocrine carcinoma of the breast: clinical, imaging, and histologic features. AJR Am J Roentgenol 2014; 203:W221-30. [PMID: 25055297 DOI: 10.2214/ajr.13.10749] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
OBJECTIVE The purpose of this study was to evaluate the clinical, imaging, and histopathologic findings of primary neuroendocrine carcinoma of the breast. MATERIALS AND METHODS A pathology database was searched for the records of patients with a histopathologic diagnosis of primary neuroendocrine carcinoma of the breast who had undergone mammography, sonography, or MRI between 1984 and 2011. The imaging studies of eligible patients were retrospectively reviewed according to the BI-RADS lexicon, and clinical presentation and histopathologic characteristics were documented. Imaging characteristics were compared with historical controls of invasive mammary carcinoma. RESULTS Eighty-seven patients (84 women, three men; mean age, 62.9 years; range, 28-89 years) were included in the study. The mean tumor size was 3.1 cm (range, 0.6-11 cm). Sixty-five of 84 (77.4%) cancers were estrogen and progesterone receptor positive and ERBB2 negative. A palpable mass (55.8%) was a common clinical manifestation. A high-density, round or oval, or lobular mass with nonspiculated margins on mammograms and an irregular (65.4%), hypoechoic (78.4%) mass, with indistinct margins (43.5%), no or enhanced posterior acoustic features (77.9%) on sonograms were common findings. MRI revealed an irregular mass (83.3%), irregular margins (63.6%), and washout kinetics (85.7%). Neuroendocrine carcinoma presented more frequently as masses on mammograms. Calcifications were infrequent compared with their occurrence in invasive mammary cancer. CONCLUSION Primary neuroendocrine carcinoma of the breast has mammographic features that differ from those of invasive mammary carcinoma. A round, oval, or lobular mass with nonspiculated margins, positive estrogen and progesterone receptor results, and negative ERBB2 results should raise suspicion of primary neuroendocrine carcinoma.
Collapse
|
9
|
Neuroendocrine breast tumours: Breast cancer or neuroendocrine cancer presenting in the breast? Breast 2014; 23:120-7. [DOI: 10.1016/j.breast.2013.11.005] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2013] [Revised: 10/31/2013] [Accepted: 11/15/2013] [Indexed: 11/22/2022] Open
|
10
|
Valentim MH, Monteiro V, Marques JC. Primary neuroendocrine breast carcinoma: a case report and literature review. Radiol Bras 2014; 47:125-7. [PMID: 25741062 PMCID: PMC4337150 DOI: 10.1590/s0100-39842014000200017] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2012] [Accepted: 07/18/2013] [Indexed: 11/21/2022] Open
Abstract
The authors present a case of a neuroendocrine carcinoma in an asymptomatic 75-year-old woman, detected in routine breast screening. The lesion was visible at mammography as a well circumscribed, medium density nodule, with no associated microcalcifications, and at ultrasonography as a hypoechoic nodule, with irregular shape and ill-defined margins. Magnetic resonance imaging revealed findings consistent with malignancy.
Collapse
Affiliation(s)
| | - Vanessa Monteiro
- MD, Specialist of Radiology, Hospital Beatriz Ângelo, Loures,
Portugal
| | - José Carlos Marques
- MD, Specialist of Radiology, Graduate Assistant, Instituto
Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
| |
Collapse
|
11
|
Aksoy F, Gündeş E, Vatansev C, Çakır M, Toy H, Emlik GD. Primary Neuroendocrine Carcinoma of the Breast: A Report of Three Cases. THE JOURNAL OF BREAST HEALTH 2014; 10:125-128. [PMID: 28331657 DOI: 10.5152/tjbh.2014.1557] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/12/2012] [Accepted: 11/23/2012] [Indexed: 11/22/2022]
Abstract
Primary neuroendocrine carcinoma of the breast is extremely rare. More than 97% of neuroendocrine tumors occur in the gastrointestinal and respiratory tracts. Three cases that have been operated in our clinic and had a diagnosis of primary neuroendocrine carcinoma of the breast were assessed, along with literature data. Histopathological diagnoses were obtained by preoperative core needle biopsy. Breast-conserving surgery was performed in two cases, and modified radical mastectomy in one. In all cases, immunohistochemical studies were positive for neuron-specific enolase and synaptophysin. All patients received adjuvant chemotherapy (CT) and one patient received additional radiotherapy (RT). Recurrence or distant metastasis was not detected during long-term follow-up after surgery.
Collapse
Affiliation(s)
- Faruk Aksoy
- Department of Generel Surgery, Necmettin Erbakan University Faculty of Medicicine, Konya, Turkey
| | - Ebubekir Gündeş
- Department of Generel Surgery, Necmettin Erbakan University Faculty of Medicicine, Konya, Turkey
| | - Celalettin Vatansev
- Department of Generel Surgery, Necmettin Erbakan University Faculty of Medicicine, Konya, Turkey
| | - Murat Çakır
- Department of Generel Surgery, Necmettin Erbakan University Faculty of Medicicine, Konya, Turkey
| | - Hatice Toy
- Department of Pathology, Necmettin Erbakan University Faculty of Medicicine, Konya, Turkey
| | - Ganime Dilek Emlik
- Departement of Radiology, Necmettin Erbakan University Faculty of Medicicine, Konya, Turkey
| |
Collapse
|
12
|
Angarita FA, Rodríguez JL, Meek E, Sánchez JO, Tawil M, Torregrosa L. Locally-advanced primary neuroendocrine carcinoma of the breast: case report and review of the literature. World J Surg Oncol 2013; 11:128. [PMID: 23734899 PMCID: PMC3682896 DOI: 10.1186/1477-7819-11-128] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2012] [Accepted: 05/13/2013] [Indexed: 12/14/2022] Open
Abstract
Background Primary neuroendocrine carcinoma of the breast is a heterogeneous group of rare tumors with positive immunoreactivity to neuroendocrine markers in at least 50% of cells. Diagnosis also requires that other primary sites be ruled out and that the same tumor show histological evidence of a breast in situ component. Primary neuroendocrine carcinoma of the breast rarely presents as locally advanced disease and less frequently with such widespread metastatic disease as described herein. The review accompanying this case report is the first to provide an overview of all the cases of primary neuroendocrine carcinoma of the breast published in the literature and encompasses detailed information regarding epidemiology, histogenesis, clinical and histologic diagnosis criteria, classification, surgical and adjuvant treatment, as well as prognosis. We also provide recommendations for common clinical and histologic pitfalls associated with this tumor. Case presentation We describe a case of a 51-year-old Hispanic woman initially diagnosed with locally-advanced invasive ductal carcinoma that did not respond to neodjuvant treatment. After undergoing modified radical mastectomy the final surgical pathology showed evidence of alveolar-type primary neuroendocrine carcinoma of the breast. The patient was treated with cisplatin/etoposide followed by paclitaxel/carboplatinum. Thirteen months after surgery the patient is alive, but developed pulmonary, bone, and hepatic metastasis. Conclusion The breast in situ component of primary neuroendocrine carcinoma of the breast may prevail on a core biopsy samples increasing the probability of underdiagnosing this tumor preoperatively. Being aware of the existence of this disease allows for timely diagnosis and management. Optimal treatment requires simultaneous consideration of both the neuroendocrine and breast in situ tumor features.
Collapse
Affiliation(s)
- Fernando A Angarita
- Department of Surgery, Hospital Universitario San Ignacio, Pontificia Universidad Javeriana, Bogotá, Colombia
| | | | | | | | | | | |
Collapse
|
13
|
Menéndez P, García E, Rabadán L, Pardo R, Padilla D, Villarejo P. Primary Neuroendocrine Breast Carcinoma. Clin Breast Cancer 2012; 12:300-3. [DOI: 10.1016/j.clbc.2012.03.001] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2012] [Accepted: 03/11/2012] [Indexed: 11/25/2022]
|
14
|
A rare case report of a primary large-cell neuroendocrine carcinoma of the breast with coexisting Paget disease. Clin Imaging 2012; 36:599-601. [PMID: 22920370 DOI: 10.1016/j.clinimag.2011.10.004] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2011] [Revised: 10/04/2011] [Accepted: 10/07/2011] [Indexed: 11/20/2022]
Abstract
Neuroendocrine carcinomas are malignancies deriving from neuroendocrine cells existing in various sites of the body, most commonly in the lungs and gastrointestinal tract. Primary neuroendocrine carcinomas of the breast are extremely rare, and their diagnosis is confirmed by positive neuroendocrine markers. We describe a case of a 46-year-old woman with a palpable mass in her left breast for the previous 3 months. The tumor was resected and a primary large-cell neuroendocrine tumor of the breast was confirmed by histopathologic examination. Paget disease of the nipple was noted as well.
Collapse
|
15
|
Alkaied H, Harris K, Brenner A, Awasum M, Varma S. Does hormonal therapy have a therapeutic role in metastatic primary small cell neuroendocrine breast carcinoma? Case report and literature review. Clin Breast Cancer 2012; 12:226-30. [PMID: 22424945 DOI: 10.1016/j.clbc.2012.01.008] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2011] [Revised: 12/25/2011] [Accepted: 01/20/2012] [Indexed: 10/28/2022]
Abstract
Primary neuroendocrine carcinoma of breast (NECB) is a very rare tumor; the World Health Organization(WHO) subcategorized these tumors into 3 major histologic subtypes: solid, small cell carcinoma (SMCC), and large cell NE carcinoma. The SMCC subtype is the least common and most aggressive and has been reported to be as aggressive as its pulmonary counterpart. SMCC is usually confirmed based on clinical, pathologic,and imaging studies. Local disease is usually managed in a fashion similar to that of the usual ductal breast cancer; in the metastatic SMCC setting, regimens that are implemented in small cell lung cancer are usually attempted, according to case reports and published small case series. Hormone receptors can be expressed in more than 90% of the solid tumor subtype; however its expression is manifested in about 50% of cases of SMCC. Although hormonal therapy can be used successfully to treat the usual metastatic ductal breast cancer,its utility in metastatic SMCC has not been reported. We report an impressive response to hormonal therapy in a patient with late relapse of breast carcinoma with a metastatic SMCC subtype that expressed hormone receptors. The response to hormonal therapy was sustained for about 12 months. The response to hormonal therapy is definitely an interesting finding that, to our knowledge, has not been described before in the setting of metastatic SMCC. We suggest considering adding hormonal therapy to the treatment pipeline for primary SMCC of the breast that express hormone receptors.
Collapse
Affiliation(s)
- Homam Alkaied
- Staten Island University Hospital, 475 Seaview Ave., Staten Island, NY 10305, USA.
| | | | | | | | | |
Collapse
|
16
|
Bourhaleb Z, Uri N, Haddad H, Azzouzi S, Zamiati S, Benchakroun N, Tawfiq N, Jouhadi H, Sahraoui S, Benider A. [Neuroendocrine carcinoma with large cells of the breast: case report and review of the literature]. Cancer Radiother 2009; 13:775-7. [PMID: 19695931 DOI: 10.1016/j.canrad.2009.06.021] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2009] [Revised: 05/11/2009] [Accepted: 06/02/2009] [Indexed: 11/25/2022]
Abstract
Neuroendocrine carcinoma with large cells is a slightly different tumor from the high rank of malignity. We report a case of breast localization in a 28-year-old patient. It is a locally advanced classified T4dN1M0 tumor that required neoadjuvant chemotherapy. The clinical answer was 75% of the level of the tumor. A standard surgery mastectomy with axillary lymph node dissection was realized, followed by external radiotherapy. The anatomopathologic and the immuno-histochemical study of the operational part confirmed the diagnosis of neuroendocrine carcinoma with large cells expressing the progesterone receptor. The patient is subjected to adjuvant hormonal treatment. After a 12 months retreat, a complete remission is maintained. Considering the scarcity of neuroendocrine carcinoma with large cells of the breast, the therapeutic standard is not yet available and the forecast remains difficult to determine.
Collapse
Affiliation(s)
- Z Bourhaleb
- Centre d'oncologie, CHU Ibn Rochd-Casablanca, Morocco.
| | | | | | | | | | | | | | | | | | | |
Collapse
|